Novozymes Biopharma Collaborates with Almac in Drug Manufacture, Half Life Extension and Targeting Technologies
Combined service offers drug development companies efficiencies in time and resource.
Novozymes Biopharma has announced its new collaboration with Almac to provide a combined service for drug development applications in drug targeting and pharmacokinetic improvements.
Drug developers will now be able to utilize Almac’s manufacturing assets and protein conjugation capability to link Novozymes’ Recombumin Flex technology to their peptide and small molecule drugs. This technology has been shown to improve pharmacokinetics and drug targeting in oncology and rheumatoid arthritis.
Clients will benefit from the continuity of service provision throughout clinical development. Collaborations with commercial partners have already begun and will continue to expand in early 2014.
The focal point of this collaboration is Novozymes’ Recombumin Flex technology, which complements Almac’s capabilities in peptide and small molecule manufacutring. Novozymes’ modified amino acid sequence of human albumin has higher receptor affinity, thereby prolonging half-life and improving drug targeting.
Source: Almac
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
